Cargando…
Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends
SIMPLE SUMMARY: Accurate primary staging for determining the extent of prostate cancer is crucial for planning treatment in high-risk patients for distant metastases. Recurrence is still common after curative intent therapy, in spite of developments in the clinical nomograms for appropriate pre-trea...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582501/ https://www.ncbi.nlm.nih.gov/pubmed/34771523 http://dx.doi.org/10.3390/cancers13215360 |
_version_ | 1784597001300606976 |
---|---|
author | Manafi-Farid, Reyhaneh Ranjbar, Shaghayegh Jamshidi Araghi, Zahra Pilz, Julia Schweighofer-Zwink, Gregor Pirich, Christian Beheshti, Mohsen |
author_facet | Manafi-Farid, Reyhaneh Ranjbar, Shaghayegh Jamshidi Araghi, Zahra Pilz, Julia Schweighofer-Zwink, Gregor Pirich, Christian Beheshti, Mohsen |
author_sort | Manafi-Farid, Reyhaneh |
collection | PubMed |
description | SIMPLE SUMMARY: Accurate primary staging for determining the extent of prostate cancer is crucial for planning treatment in high-risk patients for distant metastases. Recurrence is still common after curative intent therapy, in spite of developments in the clinical nomograms for appropriate pre-treatment screening of patients for selective therapeutic approaches. This is partly due to suboptimal diagnostic performance of standard conventional imaging modalities such as computed tomography and bone scintigraphy. Molecular imaging by means of PET/CT and PET/MRI imaging using novel specific radiotracers might provide more precise staging of disease, allowing for better personalized treatments. This article reviews current developments and future trends for functional hybrid PET-targeted imaging in primary staging of prostate cancer. ABSTRACT: Accurate primary staging is the cornerstone in all malignancies. Different morphological imaging modalities are employed in the evaluation of prostate cancer (PCa). Regardless of all developments in imaging, invasive histopathologic evaluation is still the standard method for the detection and staging of the primary PCa. Magnetic resonance imaging (MRI) and computed tomography (CT) play crucial roles; however, functional imaging provides additional valuable information, and it is gaining ever-growing acceptance in the management of PCa. Targeted imaging with different radiotracers has remarkably evolved in the past two decades. [(111)In]In-capromab pendetide scintigraphy was a new approach in the management of PCa. Afterwards, positron emission tomography (PET) tracers such as [(11)C/(18)F]choline and [(11)C]acetate were developed. Nevertheless, none found a role in the primary staging. By introduction of the highly sensitive small molecule prostate-specific membrane antigen (PSMA) PET/CT, as well as recent developments in MRI and hybrid PET/MRI systems, non-invasive staging of PCa is being contemplated. Several studies investigated the role of these sophisticated modalities in the primary staging of PCa, showing promising results. Here, we recapitulate the role of targeted functional imaging. We briefly mention the most popular radiotracers, their diagnostic accuracy in the primary staging of PCa, and impact on patient management. |
format | Online Article Text |
id | pubmed-8582501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85825012021-11-12 Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends Manafi-Farid, Reyhaneh Ranjbar, Shaghayegh Jamshidi Araghi, Zahra Pilz, Julia Schweighofer-Zwink, Gregor Pirich, Christian Beheshti, Mohsen Cancers (Basel) Review SIMPLE SUMMARY: Accurate primary staging for determining the extent of prostate cancer is crucial for planning treatment in high-risk patients for distant metastases. Recurrence is still common after curative intent therapy, in spite of developments in the clinical nomograms for appropriate pre-treatment screening of patients for selective therapeutic approaches. This is partly due to suboptimal diagnostic performance of standard conventional imaging modalities such as computed tomography and bone scintigraphy. Molecular imaging by means of PET/CT and PET/MRI imaging using novel specific radiotracers might provide more precise staging of disease, allowing for better personalized treatments. This article reviews current developments and future trends for functional hybrid PET-targeted imaging in primary staging of prostate cancer. ABSTRACT: Accurate primary staging is the cornerstone in all malignancies. Different morphological imaging modalities are employed in the evaluation of prostate cancer (PCa). Regardless of all developments in imaging, invasive histopathologic evaluation is still the standard method for the detection and staging of the primary PCa. Magnetic resonance imaging (MRI) and computed tomography (CT) play crucial roles; however, functional imaging provides additional valuable information, and it is gaining ever-growing acceptance in the management of PCa. Targeted imaging with different radiotracers has remarkably evolved in the past two decades. [(111)In]In-capromab pendetide scintigraphy was a new approach in the management of PCa. Afterwards, positron emission tomography (PET) tracers such as [(11)C/(18)F]choline and [(11)C]acetate were developed. Nevertheless, none found a role in the primary staging. By introduction of the highly sensitive small molecule prostate-specific membrane antigen (PSMA) PET/CT, as well as recent developments in MRI and hybrid PET/MRI systems, non-invasive staging of PCa is being contemplated. Several studies investigated the role of these sophisticated modalities in the primary staging of PCa, showing promising results. Here, we recapitulate the role of targeted functional imaging. We briefly mention the most popular radiotracers, their diagnostic accuracy in the primary staging of PCa, and impact on patient management. MDPI 2021-10-26 /pmc/articles/PMC8582501/ /pubmed/34771523 http://dx.doi.org/10.3390/cancers13215360 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Manafi-Farid, Reyhaneh Ranjbar, Shaghayegh Jamshidi Araghi, Zahra Pilz, Julia Schweighofer-Zwink, Gregor Pirich, Christian Beheshti, Mohsen Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends |
title | Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends |
title_full | Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends |
title_fullStr | Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends |
title_full_unstemmed | Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends |
title_short | Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends |
title_sort | molecular imaging in primary staging of prostate cancer patients: current aspects and future trends |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582501/ https://www.ncbi.nlm.nih.gov/pubmed/34771523 http://dx.doi.org/10.3390/cancers13215360 |
work_keys_str_mv | AT manafifaridreyhaneh molecularimaginginprimarystagingofprostatecancerpatientscurrentaspectsandfuturetrends AT ranjbarshaghayegh molecularimaginginprimarystagingofprostatecancerpatientscurrentaspectsandfuturetrends AT jamshidiaraghizahra molecularimaginginprimarystagingofprostatecancerpatientscurrentaspectsandfuturetrends AT pilzjulia molecularimaginginprimarystagingofprostatecancerpatientscurrentaspectsandfuturetrends AT schweighoferzwinkgregor molecularimaginginprimarystagingofprostatecancerpatientscurrentaspectsandfuturetrends AT pirichchristian molecularimaginginprimarystagingofprostatecancerpatientscurrentaspectsandfuturetrends AT beheshtimohsen molecularimaginginprimarystagingofprostatecancerpatientscurrentaspectsandfuturetrends |